{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammatory+markers&page=8",
    "query": {
      "intervention": "Inflammatory markers",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 235,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammatory+markers&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Inflammatory+markers&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T13:22:29.569Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05371340",
      "title": "Quercetin's Effect on Bone Health and Inflammatory Markers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoporosis, Postmenopausal"
      ],
      "interventions": [
        {
          "name": "Quercetin (500 mg)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo (500 mg)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Kennesaw State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 75 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2019-08-27",
      "completion_date": "2020-04-27",
      "has_results": false,
      "last_update_posted_date": "2022-05-12",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Kennesaw, Georgia",
      "locations": [
        {
          "city": "Kennesaw",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05371340"
    },
    {
      "nct_id": "NCT04566562",
      "title": "Blood Brain Barrier Dysfunction and Postoperative Neurocognitive Disorders",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurocognitive Disorders",
        "Postoperative Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Brain Imaging",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Cognitive Testing",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Blood Biomarkers",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "65 Years to 75 Years"
      },
      "enrollment_count": 32,
      "start_date": "2020-08-03",
      "completion_date": "2024-02-29",
      "has_results": false,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04566562"
    },
    {
      "nct_id": "NCT06056596",
      "title": "Lamivudine and Plasma Markers of Inflammation in Retinal Detachment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Retinal Detachment",
        "Rhegmatogenous Retinal Detachment"
      ],
      "interventions": [
        {
          "name": "Lamivudine 300 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 2,
      "start_date": "2024-01-30",
      "completion_date": "2024-09-06",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06056596"
    },
    {
      "nct_id": "NCT00340119",
      "title": "Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "End Stage Renal Disease",
        "ESRD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 871,
      "start_date": "2005-03-21",
      "completion_date": "2012-03-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00340119"
    },
    {
      "nct_id": "NCT00125060",
      "title": "Transesophageal Magnetic Resonance Imaging (MRI) in Conjunction With Lipid Lowering Measures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Diseases"
      ],
      "interventions": [
        {
          "name": "Simvastatin (20mg versus 80mg/day)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 72,
      "start_date": "2000-08",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2017-08-24",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125060"
    },
    {
      "nct_id": "NCT04259125",
      "title": "Evaluating the Role of Inflammation in Neonatal Epileptogenesis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neonatal Seizure",
        "Epilepsy",
        "Seizures",
        "Inflammatory Response"
      ],
      "interventions": [
        {
          "name": "Blood draw",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "4 Days",
        "sex": "ALL",
        "summary": "1 Day to 4 Days"
      },
      "enrollment_count": 72,
      "start_date": "2018-12-15",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 4,
      "location_summary": "Oakland, California • San Francisco, California • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04259125"
    },
    {
      "nct_id": "NCT02253394",
      "title": "The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan plus Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Ambrisentan plus Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-09",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02253394"
    },
    {
      "nct_id": "NCT01248286",
      "title": "Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Prediabetes"
      ],
      "interventions": [
        {
          "name": "Whole grain rice",
          "type": "OTHER"
        },
        {
          "name": "Refined grain rice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2010-11",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2013-10-22",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01248286"
    },
    {
      "nct_id": "NCT00204698",
      "title": "Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Laryngopharyngeal Reflux"
      ],
      "interventions": [
        {
          "name": "Aciphex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2003-08",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2008-01-16",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00204698"
    },
    {
      "nct_id": "NCT03829046",
      "title": "The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atherosclerotic Vascular Disease",
        "Type2 Diabetes",
        "Microvascular Dysfunction"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Evolocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert Rosenson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-06-03",
      "completion_date": "2021-11-15",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-10-22T13:22:29.569Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829046"
    }
  ]
}